First, a study where they gave HCQ early, in reasonable dose, as soon as people tested positive, and they also monitored zinc levels:
https://www.sciencedirect.com/science/article/pii/S147789...

Average days hospitalized was reduced from 9.2 days to 7.3 days. Patient ending up in the ICU was reduced from 6.8% to .8%, and the death rate was reduced from 3.1% to 0.5%. In total, "poor clinical outcomes", as defined by death, transfer to ICU, or hospitalization for over 10 days, was reduced from 17.6% to 3.9%. In 0.67% of patients, QTc elongation was noted, and they were removed from HCQ. No deaths were reported due to HCQ.

For severe cases, Tocilizumab, which targets IL-6 receptors to block cytokine storms, works:
https://www.thelancet.com/journals/lanrhe/article/PIIS266...
Looking at severe cases, 20% died with standard care, compared to 7% who got Tocilizumab.

So does Anakinra, which blocks IL-1 receptors:
https://www.thelancet.com/journals/lanrhe/article/PIIS266...
Patients included people with severe bilateral pneumonia. Negative outcomes (admission to ICU or death) occurred in 25% of cases that received Anakinra, compare to 75% of patients on standard care. Anakinra reduced both mortality and the need for mechanical ventilation without significant side effects.